EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study

Ludovic Gabellier, Pierre Peterlin, Sylvain Thepot, Yosr Hicheri, Franciane Paul, Maria Pilar Gallego-Hernanz, Sarah Bertoli, Pascal Turlure, Arnaud Pigneux, Romain Guieze, Marlène Ochmann, Jean-Valère Malfuson und 7 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05623-0 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Ludovic Gabellier und 18 weiteren Autor:innen. Beteiligte Einrichtung: Département d'Hématologie Clinique, CHU Montpellier, Université Montpellier-Nîmes, 80, Avenue Augustin Fliche, 34090, Montpellier, France. l-gabellie…. Hauptthemen laut MEDLINE: Azacitidine, Leukemia, Myeloid, Acute. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Very few data are available about hypomethylating agent (HMA) efficiency in core binding factor acute myeloid leukemias (CBF-AML). Our main objective was to evaluate the efficacy and safety of HMA in the specific subset of CBF-AML. Here, we report the results of a multicenter retrospective French study about efficacy of HMA monotherapy, used frontline or for R/R CBF-AML. Forty-nine patients were included, and received a median of 5 courses of azacitidine ( n = 46) or decitabine ( n = 3). ORR was 49% for the whole cohort with a median time to response of 112 days. After a median follow-up of 72.3 months, median OS for the total cohort was 10.6 months. In multivariate analysis, hematological relapse of CBF-AML at HMA initiation was significantly associated with a poorer OS (HR: 2.13; 95%CI: 1.04–4.36; p = 0.038). Responders had a significantly improved OS (1-year OS: 75%) compared to non-responders (1-year OS: 15.3%; p < 0.0001). Hematological improvement occurred for respectively 28%, 33% and 48% for patients who were red blood cell or platelet transfusion-dependent, or who experienced grade 3/4 neutropenia at HMA initiation. Adverse events were consistent with the known safety profile of HMA. Our study highlights that HMA is a well-tolerated therapeutic option with moderate clinical activity for R/R CBF-AML and for patients who cannot handle intensive chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzacitidineLeukemia, Myeloid, AcuteHumansRetrospective StudiesDecitabineCore Binding FactorsAntineoplastic Combined Chemotherapy ProtocolsTreatment Outcome

Stichwörter der Autor:innen

Acute myeloid leukemiaAzacitidineCore binding factorDecitabineHypomethylating agents

Substanzen

DecitabineAzacitidineCore Binding Factors

Autor:innen und Institutionen

  • Département d'Hématologie Clinique, CHU Montpellier, Université Montpellier-Nîmes, 80, Avenue Augustin Fliche, 34090, Montpellier, France. l-gabellier@chu-montpellier.fr.
  • Département d'Hématologie Clinique, CHU Nantes, Université de Nantes, Nantes, France.
  • Département d'Hématologie Clinique, CHU Angers, Université d'Angers, Angers, France.
  • Département d'Hématologie Clinique, Institut Paoli-Calmettes, Marseille, France.
  • Département d'Hématologie Clinique, CHU Montpellier, Université Montpellier-Nîmes, 80, Avenue Augustin Fliche, 34090, Montpellier, France.
  • Département d'Hématologie Clinique, CHU Poitiers, Université de Poitiers, Poitiers, France.

Zitieren

APA

Gabellier, L., Peterlin, P., Thepot, S., Hicheri, Y., Paul, F., Gallego-Hernanz, M. P., Bertoli, S., Turlure, P., Pigneux, A., Guieze, R., Ochmann, M., Malfuson, J. V., Cluzeau, T., Thomas, X., Tavernier, E., Jourdan, E., Bonnet, S., Tudesq, J. J., & Raffoux, E. (2024). Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05623-0

Vancouver

Gabellier L, Peterlin P, Thepot S, Hicheri Y, Paul F, Gallego-Hernanz MP, et al. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05623-0

BibTeX
@article{Gabellier2024,
  author = {Gabellier, Ludovic and Peterlin, Pierre and Thepot, Sylvain and Hicheri, Yosr and Paul, Franciane and Gallego-Hernanz, Maria Pilar and Bertoli, Sarah and Turlure, Pascal and Pigneux, Arnaud and Guieze, Romain and Ochmann, Marlène and Malfuson, Jean-Valère and Cluzeau, Thomas and Thomas, Xavier and Tavernier, Emmanuelle and Jourdan, Eric and Bonnet, Sarah and Tudesq, Jean-Jacques and Raffoux, Emmanuel},
  title = {Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05623-0}
}
Kostenlos starten →